clinical trial · NCT05224102
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Genentech, Inc.·phase4·active not recruiting·n = 218
Diabetic Macular EdemaFaricimab
brief summary
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
started
Feb 28, 2022
primary completion
Jan 26, 2027
completion
Jan 26, 2027
last updated
Aug 25, 2026
official title
A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol